USNA Usana Health Sciences Inc

Price (delayed)

$96.36

Market cap

$1.95B

P/E Ratio

15.72

Dividend/share

N/A

EPS

$6.13

Enterprise value

$1.69B

Highlights
The EPS has grown by 32% YoY and by 4.1% from the previous quarter
USNA's net income is up by 25% year-on-year and by 3.3% since the previous quarter
The company's equity rose by 27% YoY but it fell by 9% QoQ
The price to earnings (P/E) is 19% lower than the 5-year quarterly average of 19.1 but 9% higher than the last 4 quarters average of 14.2

Key stats

What are the main financial stats of USNA
Market
Shares outstanding
20.24M
Market cap
$1.95B
Enterprise value
$1.69B
Valuations
Price to earnings (P/E)
15.72
Price to book (P/B)
4.99
Price to sales (P/S)
1.71
EV/EBIT
9.22
EV/EBITDA
8.22
EV/Sales
1.44
Earnings
Revenue
$1.18B
EBIT
$183.61M
EBITDA
$205.86M
Free cash flow
$139.87M
Per share
EPS
$6.13
Free cash flow per share
$6.69
Book value per share
$19.32
Revenue per share
$56.29
TBVPS
$25.7
Balance sheet
Total assets
$584.51M
Total liabilities
$181.74M
Debt
$0
Equity
$402.78M
Working capital
$221.73M
Liquidity
Debt to equity
0
Current ratio
2.46
Quick ratio
1.7
Net debt/EBITDA
-1.25
Margins
EBITDA margin
17.5%
Gross margin
81.2%
Net margin
10.9%
Operating margin
15.4%
Efficiency
Return on assets
22.2%
Return on equity
32.5%
Return on invested capital
169.9%
Return on capital employed
42.4%
Return on sales
15.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

USNA stock price

How has the Usana Health Sciences stock price performed over time
Intraday
1.48%
1 week
-1.71%
1 month
-5.64%
1 year
15.76%
YTD
24.98%
QTD
-5.93%

Financial performance

How have Usana Health Sciences's revenue and profit performed over time
Revenue
$1.18B
Gross profit
$955.3M
Operating income
$181.68M
Net income
$128.73M
Gross margin
81.2%
Net margin
10.9%
USNA's net income is up by 25% year-on-year and by 3.3% since the previous quarter
The operating income has increased by 21% year-on-year and by 2.9% since the previous quarter
USNA's revenue is up by 12% year-on-year and by 3.6% since the previous quarter
USNA's net margin is up by 11% YoY

Growth

What is Usana Health Sciences's growth rate over time

Valuation

What is Usana Health Sciences stock price valuation
P/E
15.72
P/B
4.99
P/S
1.71
EV/EBIT
9.22
EV/EBITDA
8.22
EV/Sales
1.44
The EPS has grown by 32% YoY and by 4.1% from the previous quarter
The price to earnings (P/E) is 19% lower than the 5-year quarterly average of 19.1 but 9% higher than the last 4 quarters average of 14.2
The company's equity rose by 27% YoY but it fell by 9% QoQ
USNA's P/B is 17% above its last 4 quarters average of 4.2
USNA's price to sales (P/S) is 13% more than its last 4 quarters average of 1.5
USNA's revenue is up by 12% year-on-year and by 3.6% since the previous quarter

Efficiency

How efficient is Usana Health Sciences business performance
The company's return on invested capital rose by 21% YoY
The ROE has grown by 8% YoY but it has contracted by 2.4% from the previous quarter
The ROS has grown by 7% YoY
Usana Health Sciences's ROA has increased by 7% YoY

Dividends

What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for USNA.

Financial health

How did Usana Health Sciences financials performed over time
The total assets has grown by 23% YoY but it has contracted by 9% from the previous quarter
Usana Health Sciences's total liabilities has increased by 16% YoY but it has decreased by 9% QoQ
USNA's debt is 100% less than its equity
The company's equity rose by 27% YoY but it fell by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.